Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: CharlestonBuckeye who wrote (12878)	5/23/2014 8:21:57 PM
From: Mimbari	2 Recommendations Recommended By Jack Russell travisnye Read Replies (1) \| Respond to of 13111

I see things differently. I think FDA changed it on them like they probably did four times before. Common sense says you do what they say. Four times they met with FDA on this. Why would they ignore the first advice? FDA is delaying this for reasons we cannot know. But I suspect the impact of having game changing drug changes the playing field too much. It is disruptive new technology. Billions and billions of current drug sales are at stake. And don't think for a moment the FDA doesn't feel that pressure.